Specify a stock or a cryptocurrency in the search bar to get a summary
SynAct Pharma AB
SYNACTSynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden. Address: Medicon Village, Lund, Sweden, 223 81
Analytics
WallStreet Target Price
163 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SYNACT
Dividend Analytics SYNACT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SYNACT
Stock Valuation SYNACT
Financials SYNACT
Results | 2019 | Dynamics |